Unknown

Dataset Information

0

Mavrilimumab for severe COVID-19 - Authors' reply.

ABSTRACT:

SUBMITTER: De Luca G 

PROVIDER: S-EPMC7837188 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Mavrilimumab for severe COVID-19 - Authors' reply.

De Luca Giacomo G   Cavalli Giulio G   Campochiaro Corrado C   Della-Torre Emanuel E   Dagna Lorenzo L  

The Lancet. Rheumatology 20200905 11

Similar Datasets

Unknown Tocilizumab for severe COVID-19 pneumonia - Authors' reply.
| S-EPMC7431126 | biostudies-literature
Unknown Multiomics single timepoint measurements to predict severe COVID-19 - Authors' reply.
| S-EPMC9876580 | biostudies-literature
Unknown Cancer and COVID-19 - Authors' reply.
| S-EPMC7544437 | biostudies-literature
Unknown Authors' reply: Hypoalbuminemia in COVID-19.
| S-EPMC8662292 | biostudies-literature
Unknown COVID-19 in pregnant women - Authors' reply.
| S-EPMC7195406 | biostudies-literature
Unknown Surgery during the COVID-19 pandemic - Authors' reply.
| S-EPMC7833325 | biostudies-literature
Unknown Depression and anxiety during COVID-19 - Authors' reply.
| S-EPMC8813062 | biostudies-literature
Unknown Baricitinib for COVID-19: a suitable treatment? - Authors' reply.
| S-EPMC7271155 | biostudies-literature
Unknown Efficacy matters: broadening complement inhibition in COVID-19 - Authors' reply.
| S-EPMC7834467 | biostudies-literature
Unknown Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.
| S-EPMC8298006 | biostudies-literature